Literature DB >> 11123976

Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.

G Minotti1, S Licata, A Saponiero, P Menna, A M Calafiore, G Di Giammarco, G Liberi, F Animati, A Cipollone, S Manzini, C A Maggi.   

Abstract

Secondary alcohol metabolites have been proposed to mediate chronic cardiotoxicity induced by doxorubicin (DOX) and other anticancer anthracyclines. In this study, NADPH-supplemented human cardiac cytosol was found to reduce the carbonyl group in the side chain of the tetracyclic ring of DOX, producing the secondary alcohol metabolite doxorubicinol (DOXol). A decrease in the level of alcohol metabolite formation was observed by replacing DOX with epirubicin (EPI), a less cardiotoxic analogue characterized by an axial-to-equatorial epimerization of the hydroxyl group at C-4 in the amino sugar bound to the tetracyclic ring (daunosamine). A similar decrease was observed by replacing DOX with MEN 10755, a novel anthracycline with preclinical evidence of reduced cardiotoxicity. MEN 10755 is characterized by the lack of a methoxy group at C-4 in the tetracyclic ring and by intercalation of 2, 6-dideoxy-L-fucose between daunosamine and the aglycone. Multiple comparisons with methoxy- or 4-demethoxyaglycones, and a number of mono- or disaccharide 4-demethoxyanthracyclines, showed that both the lack of the methoxy group and the presence of a disaccharide moiety limited alcohol metabolite formation by MEN 10755. Studies with enzymatically generated or purified anthracycline secondary alcohols also showed that the presence of a disaccharide moiety, but not the lack of a methoxy group, made the metabolite of MEN 10755 less reactive with the [4Fe-4S] cluster of cytoplasmic aconitase, as evidenced by its limited reoxidation to the parent carbonyl anthracycline and by a reduced level of delocalization of Fe(II) from the cluster. Collectively, these studies (i) characterize the different influence of methoxy and sugar substituents on the formation and [4Fe-4S] reactivity of anthracycline secondary alcohols, (ii) lend support to the role of alcohol metabolites in anthracycline-induced cardiotoxicity, as they demonstrate that the less cardiotoxic EPI and MEN 10755 share a reduction in the level of formation of such metabolites, and (iii) suggest that the cardiotoxicity of MEN 10755 might be further decreased by the reduced [4Fe-4S] reactivity of its alcohol metabolite.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123976     DOI: 10.1021/tx000143z

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  15 in total

Review 1.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

2.  Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.

Authors:  Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Michael J Rieder; Amit P Bhavsar; Shubhayan Sanatani; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton
Journal:  Br J Clin Pharmacol       Date:  2017-03-19       Impact factor: 4.335

3.  Tandem laser-induced fluorescence and mass spectrometry detection for high-performance liquid chromatography analysis of the in vitro metabolism of doxorubicin.

Authors:  Joseph B Katzenmeyer; Christopher V Eddy; Edgar A Arriaga
Journal:  Anal Chem       Date:  2010-10-01       Impact factor: 6.986

4.  Metal Nanoshell - Capsule for Light-Driven Release of Small Molecule.

Authors:  Jian Zhang; Yi Fu; Feng Jiang; Joseph R Lakowicz
Journal:  J Phys Chem C Nanomater Interfaces       Date:  2010-04-02       Impact factor: 4.126

5.  Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking.

Authors:  Praveena Mohan; Natalya Rapoport
Journal:  Mol Pharm       Date:  2010-10-27       Impact factor: 4.939

6.  Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.

Authors:  G Minotti; M Parlani; E Salvatorelli; P Menna; A Cipollone; F Animati; C A Maggi; S Manzini
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 7.  Cardiac toxicity: old and new issues in anti-cancer drugs.

Authors:  M Sereno; A Brunello; A Chiappori; J Barriuso; E Casado; C Belda; J de Castro; J Feliu; M González-Barón
Journal:  Clin Transl Oncol       Date:  2008-01       Impact factor: 3.405

8.  Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.

Authors:  Giuseppe Sacco; Rossella Giampietro; Emanuela Salvatorelli; Pierantonio Menna; Nicoletta Bertani; Gallia Graiani; Fabio Animati; Cristina Goso; Carlo A Maggi; Stefano Manzini; Giorgio Minotti
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

9.  Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity.

Authors:  Yunfang Zhang; Haitham El-Sikhry; Ketul R Chaudhary; Sri Nagarjun Batchu; Anooshirvan Shayeganpour; Taibeh Orujy Jukar; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Page Myers; Douglas C Rouse; Julie Foley; Abraham Nyska; Darryl C Zeldin; John M Seubert
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

Review 10.  Iron-regulatory proteins: molecular biology and pathophysiological implications.

Authors:  Gaetano Cairo; Stefania Recalcati
Journal:  Expert Rev Mol Med       Date:  2007-12-05       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.